Literature DB >> 9365245

Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NFkappaB p65 protein expression.

R Visconti1, J Cerutti, S Battista, M Fedele, F Trapasso, K Zeki, M P Miano, F de Nigris, L Casalino, F Curcio, M Santoro, A Fusco.   

Abstract

We have investigated the role of the NFkappaB complex in the process of thyroid carcinogenesis by analysing thyroid carcinoma cell lines. A significant increase in p65 NFkappaB mRNA and protein expression, compared to normal thyroid cultures or tissue, was found in all of the cancer cell lines. Conversely, only a modest increase in the p50 NFkappaB mRNA and protein was found in most, but not all carcinoma cell lines. The block of p65 protein synthesis with specific antisense oligonucleotides greatly reduced the ability of two undifferentiated carcinoma cell lines to form colonies in agar and reduced their growth rate. On the other hand, no effect was observed in the same cell lines when treated with p50 specific antisense oligonucleotides. These inhibitory effects seem to be mediated by the suppression of c-myc gene expression, since treatment with antisense oligonucleotides for p65 gene interfered negatively with c-myc gene expression. Our results indicate that activation of the NFkappaB complex by overexpression of p65 plays a critical role in the process of thyroid cell transformation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9365245     DOI: 10.1038/sj.onc.1201373

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  50 in total

Review 1.  NF-kappaB in pancreatic cancer.

Authors:  Guido M Sclabas; Shuichi Fujioka; Christian Schmidt; Douglas B Evans; Paul J Chiao
Journal:  Int J Gastrointest Cancer       Date:  2003

2.  A preoperative diagnostic test that distinguishes benign from malignant thyroid carcinoma based on gene expression.

Authors:  Janete M Cerutti; Rosana Delcelo; Marcelo João Amadei; Claudia Nakabashi; Rui M B Maciel; Bercedis Peterson; Jennifer Shoemaker; Gregory J Riggins
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

3.  Transcription factors in the cellular signaling network as prime targets of chemopreventive phytochemicals.

Authors:  Young-Joon Surh
Journal:  Cancer Res Treat       Date:  2004-10-30       Impact factor: 4.679

4.  Curcumin induces G2/M arrest, apoptosis, NF-κB inhibition, and expression of differentiation genes in thyroid carcinoma cells.

Authors:  Suzan Schwertheim; Frederik Wein; Klaus Lennartz; Karl Worm; Kurt Werner Schmid; Sien-Yi Sheu-Grabellus
Journal:  J Cancer Res Clin Oncol       Date:  2017-03-06       Impact factor: 4.553

Review 5.  Deregulation of microRNA expression in thyroid neoplasias.

Authors:  Pierlorenzo Pallante; Sabrina Battista; Giovanna Maria Pierantoni; Alfredo Fusco
Journal:  Nat Rev Endocrinol       Date:  2013-11-19       Impact factor: 43.330

Review 6.  The role of AP-1, NF-kappaB and ROS/NOS in skin carcinogenesis: the JB6 model is predictive.

Authors:  Arindam Dhar; Mathew R Young; Nancy H Colburn
Journal:  Mol Cell Biochem       Date:  2002 May-Jun       Impact factor: 3.396

7.  Nuclear factor-kappaB p65 (RelA) transcription factor is constitutively activated in human colorectal carcinoma tissue.

Authors:  Liang-Liang Yu; Hong-Gang Yu; Jie-Ping Yu; He-Sheng Luo; Xi-Ming Xu; Jun-Hua Li
Journal:  World J Gastroenterol       Date:  2004-11-15       Impact factor: 5.742

8.  Nuclear factor-kappaB/p65 (Rel A) is constitutively activated in human prostate adenocarcinoma and correlates with disease progression.

Authors:  Sanjeev Shukla; Gregory T MacLennan; Pingfu Fu; Jigar Patel; Susan R Marengo; Martin I Resnick; Sanjay Gupta
Journal:  Neoplasia       Date:  2004 Jul-Aug       Impact factor: 5.715

Review 9.  Molecular pathogenesis and mechanisms of thyroid cancer.

Authors:  Mingzhao Xing
Journal:  Nat Rev Cancer       Date:  2013-03       Impact factor: 60.716

Review 10.  Nf-kappa B, chemokine gene transcription and tumour growth.

Authors:  Ann Richmond
Journal:  Nat Rev Immunol       Date:  2002-09       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.